Success Metrics

Clinical Success Rate
100.0%

Based on 13 completed trials

Completion Rate
100%(13/13)
Active Trials
9(29%)
Results Posted
38%(5 trials)

Phase Distribution

Ph not_applicable
11
35%
Ph phase_1
3
10%
Ph early_phase_1
1
3%
Ph phase_2
3
10%
Ph phase_3
3
10%
Ph phase_4
1
3%

Phase Distribution

4

Early Stage

3

Mid Stage

4

Late Stage

Phase Distribution22 total trials
Early Phase 1First-in-human
1(4.5%)
Phase 1Safety & dosage
3(13.6%)
Phase 2Efficacy & side effects
3(13.6%)
Phase 3Large-scale testing
3(13.6%)
Phase 4Post-market surveillance
1(4.5%)
N/ANon-phased studies
11(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

13 of 13 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

9

trials recruiting

Total Trials

31

all time

Status Distribution
Active(11)
Completed(13)
Other(7)

Detailed Status

Completed13
Recruiting8
unknown7
Not yet recruiting2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
31
Active
9
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (4.5%)
Phase 13 (13.6%)
Phase 23 (13.6%)
Phase 33 (13.6%)
Phase 41 (4.5%)
N/A11 (50.0%)

Trials by Status

completed1342%
not_yet_recruiting26%
recruiting826%
active_not_recruiting13%
unknown723%

Recent Activity

Clinical Trials (31)

Showing 20 of 31 trialsScroll for more
NCT05976763Phase 3

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

Recruiting
NCT06078709Phase 2

Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma

Recruiting
NCT03942328Phase 1

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Recruiting
NCT06557733Phase 2

An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis

Recruiting
NCT04939051Phase 2

Obeticholic Acid for Prevention in Barrett's Esophagus

Recruiting
NCT06408220Not Applicable

Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer

Recruiting
NCT06200961Not Applicable

Trans-nasal Endoscopy for Bariatric Patients

Recruiting
NCT06017102Not Applicable

Wired Magnetically Assisted Capsule Endoscopy and Esophageal Varices

Completed
NCT05107219Phase 1

GCC Agonist Signal in the Small Intestine

Active Not Recruiting
NCT07156591

Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention

Not Yet Recruiting
NCT07152756

Impact of a One-Week Discontinuation of Semaglutide on Gastric Retention and Endoscopic Mucosal Visibility Scores

Not Yet Recruiting
NCT05634746Phase 3

24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)

Completed
NCT05875636

GLP-1 Receptor Agonist Use and Incidence of Retained Gastric Food on Endoscopy

Completed
NCT05053945

Helicobacter Pylori, Atrophic Gastritis and Intestinal Metaplasia Registry and Prospective Study

Recruiting
NCT06269380Not Applicable

Evaluation of Antral Biopsies Obtained in Normal Esophagogastroduodenoscopy

Completed
NCT05927766Not Applicable

Correlation Between Endoscopic Findings And Helicobacter Pylori Infection In Chronic Kidney Disease Patients

Unknown
NCT04281108Phase 3

Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)

Completed
NCT04301986Not Applicable

Patient Acceptance and Preference Among Screening Modalities for Detection of Barrett's Esophagus

Completed
NCT04295811Not Applicable

Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC

Unknown
NCT03990753

Microbiome/Peptidome-based Model for Non-invasive Detection of High-risk Gastroesophageal Varices in Compensated Cirrhosis (CHESS1901/APPHA1901)

Unknown

Drug Details

Intervention Type
PROCEDURE
Total Trials
31